homepage-top-section

Orca-T is being assessed to treat hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukaemia (AML), and acute lymphoblastic leukaemia (ALL). The FDA has granted priority review, with

The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several

The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in

The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology.

Genentech will obtain rights for OMass’ preclinical oral small molecule programme for IBD, as part of the agreement. OMass Therapeutics CEO Ros Deegan said: “Using our OdyssION platform,

This new dosing option enables patients with mild cognitive impairment or mild dementia to receive treatment at home, following an initial intravenous (IV) administration. Leqembi Iqlik, administered through

This collaboration appoints Optime Care as the exclusive specialty pharmacy provider for the newly FDA-approved tablets, ensuring the medication’s availability to patients.  Optime Care general manager Bill Bertetto

This new small molecule is designed for prostate cancer imaging and treatment.   The FDA’s approval allows Archeus to begin a Phase I clinical study targeting metastatic castration-resistant prostate

The therapy is intended to treat the adult population with haematological malignancies needing an allogeneic haematopoietic stem cell transplantation after a myeloablative conditioning for those individuals with no